Twogee Biotech raises 2.2 million euros in seed capital

The Munich-based biotechnology start-up Twogee Biotech has successfully completed a seed financing round of 2.16 million euros. The startup, which was founded in 2024, intends to use the fresh capital to further develop and commercialize its enzyme platform for the industrial utilization of biomass residual streams. The aim is to replace fossil and food-based raw materials in the chemical industry with sustainable second-generation (2G) alternatives.

Investors focus on enzyme technology for the circular economy

High-Tech Gründerfonds (HTGF) and Bayern Kapital are participating in the financing round. The investor consortium is complemented by strategic partners such as AgriFoodTech Venture Alliance and Heinz Entsorgung. With this round, Twogee Biotech is strengthening both its technological development and its market entry.

Enzymes as the key to utilizing biomass residual streams

Twogee Biotech develops customer-specific enzyme and production strain solutions with which previously economically underutilized biomass residue and side streams can be converted into high-quality, sustainable raw materials - in particular 2G sugars for bio and SynBio applications. In contrast to first-generation raw materials, these do not come from food-based sources.

Many industrial residues contain considerable untapped added value. We help our partners to tap into this potential with minimal integration effort and a clear economic perspective.

Frank Wallrapp, CEO of Twogee Biotech

At the heart of the approach is a predictive development platform that integrates enzyme screening, strain engineering and fermentation in an industry-oriented manner from the outset. This is intended to shorten development times and reduce risks during scale-up.

From the lab to industry: first projects already implemented

The company founded by Frank Wallrapp (CEO) and Helge Jochens (CTO) already has its own laboratories and bioreactors at the Biotechnology Innovation and Start-up Center (IZB) in Martinsried. The first MVPs are available, and paid pilot projects with industrial partners are also underway. A key element of the business model is a licensing approach that enables customers to produce enzymes locally themselves - with positive effects on costs, carbon footprint and security of supply.

2G raw materials have the chance to be a real game changer if sustainability and higher profits go hand in hand, as is the case here.

Tilmann Petersen, Investment Manager at HTGF

Capital flows into scaling, laboratories and team building

Twogee Biotech intends to use the seed capital primarily to expand its laboratory infrastructure, further develop predictive bioreactor systems and build an experienced team for process and scale-up development. The start-up is thus positioning itself as a technological development partner for industrial companies that want to transform their existing plants and material flows into circular, low-carbon value creation systems.